Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

25/08/2017


Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Bad Vilbel, August 25, 2017 –

STADA Arzneimittel AG gives notice that Carl Ferdinand Oetker, chairman of the Supervisory Board, Rolf Hoffmann, Dr. Birgit Kudlek, Tina Müller and Dr. Gunnar Riemann today have resigned from their positions on the Supervisory Board with effect from the end of September 25, 2017 in accordance with the resignation period provided by the articles of association.


The successors to the retiring members shall be appointed by court order in the near future. These changes are related to the takeover of the company by Bain Capital and Cinven.
 
Contact:
STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: leslie.iltgen@stada.de

Download in PDF format

Share:

Related Posts

STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid
STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018
The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2018.
STADA Arzneimittel AG informs about receipt of binding, conditional take-over offer
STADA Arzneimittel AG informs about receipt of binding, conditional take-over offer